MX2023002047A - Proteinas de interleucina 2 (il-2) glucosiladas y usos de las mismas. - Google Patents
Proteinas de interleucina 2 (il-2) glucosiladas y usos de las mismas.Info
- Publication number
- MX2023002047A MX2023002047A MX2023002047A MX2023002047A MX2023002047A MX 2023002047 A MX2023002047 A MX 2023002047A MX 2023002047 A MX2023002047 A MX 2023002047A MX 2023002047 A MX2023002047 A MX 2023002047A MX 2023002047 A MX2023002047 A MX 2023002047A
- Authority
- MX
- Mexico
- Prior art keywords
- seq
- sup
- sub
- tag
- sequence identity
- Prior art date
Links
- 108700003606 glycosylated interleukin 2 Proteins 0.000 title 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 abstract 3
- 102000000588 Interleukin-2 Human genes 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se relaciona con una secuencia de proteína IL-2 de fórmula (Etiqueta1)y-(Ala)x-SEC A-SEC B-SEC C--(Etiqueta2)z (I), en donde la SEC A tiene al menos 89% de identidad de secuencia con la SEC ID NO:1; la SEC B tiene al menos un 76% de identidad de secuencia con la SEC ID NO:2 y comprende al menos una porción de glucosilación; la SEC C tiene al menos 91% de identidad de secuencia con la SEC ID NO:4; Etiqueta1 y Etiqueta2 son independientemente un resto de etiqueta; Ala es un residuo de alanina; x es 0 o 1; y es 0 o 1; y z es 0 o 1; a conjugados de los mismos y sus usos en el tratamiento de trastornos de la proliferación celular.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063071627P | 2020-08-28 | 2020-08-28 | |
| EP20202306 | 2020-10-16 | ||
| EP20216067 | 2020-12-21 | ||
| EP21160466 | 2021-03-03 | ||
| EP21162023 | 2021-03-11 | ||
| PCT/EP2021/073735 WO2022043493A1 (en) | 2020-08-28 | 2021-08-27 | Glycosylated il-2 proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002047A true MX2023002047A (es) | 2023-03-15 |
Family
ID=77726468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002047A MX2023002047A (es) | 2020-08-28 | 2021-08-27 | Proteinas de interleucina 2 (il-2) glucosiladas y usos de las mismas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230340055A1 (es) |
| EP (1) | EP4204439A1 (es) |
| JP (1) | JP2023540701A (es) |
| KR (1) | KR20230057447A (es) |
| AU (1) | AU2021335032A1 (es) |
| BR (1) | BR112023003476A2 (es) |
| CA (1) | CA3189715A1 (es) |
| IL (1) | IL300668A (es) |
| MX (1) | MX2023002047A (es) |
| TW (1) | TW202219060A (es) |
| WO (1) | WO2022043493A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022014082A (es) | 2020-06-03 | 2022-12-07 | Ascendis Pharma Oncology Div A/S | Secuencias de interleucina (il-2) y usos de las mismas. |
| WO2023161371A1 (en) * | 2022-02-25 | 2023-08-31 | Danmarks Tekniske Universitet | Engineered bacteria secreting cytokines for use in cancer immunotherapy |
| WO2024054527A1 (en) * | 2022-09-06 | 2024-03-14 | The Research Institute At Nationwide Children's Hospital | Genetically engineered bone marrow derived myeloid cells for treatment of central nervous system tumors |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| US7332164B2 (en) | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
| WO2004089280A2 (en) | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
| US7690003B2 (en) | 2003-08-29 | 2010-03-30 | Fuller Jeffrey C | System and method for increasing data throughput using thread scheduling |
| WO2005027978A2 (en) | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| JP2007527242A (ja) * | 2004-03-05 | 2007-09-27 | カイロン コーポレーション | 治療剤の患者耐容性を予測するためのインビトロ試験システム |
| US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
| CA2662978A1 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Hindered ester-based biodegradable linkers for oligonucleotide delivery |
| NZ580670A (en) | 2007-06-21 | 2011-09-30 | Univ Muenchen Tech | Biological active proteins having increased in vivo and/or vitro stability |
| TW200922624A (en) | 2007-07-11 | 2009-06-01 | Enzon Pharmaceuticals Inc | Polymeric drug delivery system containing a multi-substituted aromatic moiety |
| HRP20191052T1 (hr) | 2008-02-01 | 2019-11-01 | Ascendis Pharma As | Predlijek koji obuhvaća samocijepajuću poveznicu |
| ES2875426T3 (es) | 2008-04-29 | 2021-11-10 | Ascendis Pharma Endocrinology Div A/S | Compuestos de hormona de crecimiento humana recombinante pegilada |
| CA2723263A1 (en) | 2008-05-23 | 2009-11-26 | Enzon Pharmaceuticals, Inc. | Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides |
| EP2382228B2 (en) * | 2009-01-21 | 2026-01-07 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
| EA020843B1 (ru) | 2009-02-03 | 2015-02-27 | Амуникс Оперейтинг Инк. | Удлиненные рекомбинантные полипептиды и содержащие их композиции |
| KR101770844B1 (ko) | 2009-07-31 | 2017-08-23 | 아센디스 파마 에이에스 | 폴리에틸렌 글리콜 기반의 생분해성 수불용성 하이드로겔 |
| US20120289571A1 (en) | 2009-12-31 | 2012-11-15 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates of aromatic amine containing compounds including releasable urea linker |
| WO2011140392A1 (en) | 2010-05-05 | 2011-11-10 | Prolynx Llc | Controlled drug release from solid supports |
| EP2566335B1 (en) | 2010-05-05 | 2016-06-29 | Prolynx Llc | Controlled release of active compounds from macromolecular conjugates |
| JP5594791B2 (ja) | 2010-06-30 | 2014-09-24 | Ｎｅｃソリューションイノベータ株式会社 | 属性判定方法、属性判定装置、プログラム、記録媒体および属性判定システム |
| EP2741778A1 (en) | 2011-08-12 | 2014-06-18 | Ascendis Pharma A/S | Polymeric hyperbranched carrier-linked prodrugs |
| CA2848142C (en) | 2011-09-07 | 2021-05-18 | Prolynx Llc | Hydrogels with biodegradable crosslinking |
| WO2013036857A1 (en) | 2011-09-07 | 2013-03-14 | Prolynx Llc | Sulfone linkers |
| US9855340B2 (en) | 2012-10-11 | 2018-01-02 | Ascendis Pharma A/S | Hydrogel prodrugs |
| CN104955472A (zh) | 2012-10-17 | 2015-09-30 | 诺和诺德保健股份有限公司 | 用于生长激素递送的脂肪酸酰化的氨基酸 |
| US11633487B2 (en) | 2014-08-06 | 2023-04-25 | Ascendis Pharma A/S | Prodrugs comprising an aminoalkyl glycine linker |
| AU2017292934B9 (en) | 2016-07-07 | 2024-08-29 | Bolt Biotherapeutics, Inc. | Antibody adjuvant conjugates |
| WO2018112108A1 (en) | 2016-12-13 | 2018-06-21 | Bolt Biotherapeutics, Inc. | Antibody adjuvant conjugates |
| KR102715397B1 (ko) | 2017-03-22 | 2024-10-10 | 아센디스 파마 에이에스 | 히드로겔 가교된 히알루론산 전구약물 조성물 및 방법 |
| JP7490563B2 (ja) | 2018-03-28 | 2024-05-27 | アセンディス ファーマ オンコロジー ディヴィジョン エー／エス | Ｉｌ－２コンジュゲート |
| JP2022501009A (ja) * | 2018-09-21 | 2022-01-06 | イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド | 新規インターロイキン２およびその使用 |
| JP2022516308A (ja) | 2019-01-04 | 2022-02-25 | アセンディス ファーマ オンコロジー ディヴィジョン エー／エス | パターン認識受容体アゴニストのコンジュゲート |
| SG11202110436UA (en) | 2019-04-05 | 2021-10-28 | Prolynx Llc | Improved conjugation linkers |
| MX2022014082A (es) * | 2020-06-03 | 2022-12-07 | Ascendis Pharma Oncology Div A/S | Secuencias de interleucina (il-2) y usos de las mismas. |
-
2021
- 2021-08-27 TW TW110131778A patent/TW202219060A/zh unknown
- 2021-08-27 CA CA3189715A patent/CA3189715A1/en active Pending
- 2021-08-27 KR KR1020237010467A patent/KR20230057447A/ko active Pending
- 2021-08-27 US US18/043,319 patent/US20230340055A1/en active Pending
- 2021-08-27 AU AU2021335032A patent/AU2021335032A1/en active Pending
- 2021-08-27 IL IL300668A patent/IL300668A/en unknown
- 2021-08-27 MX MX2023002047A patent/MX2023002047A/es unknown
- 2021-08-27 EP EP21769416.5A patent/EP4204439A1/en active Pending
- 2021-08-27 JP JP2023513563A patent/JP2023540701A/ja active Pending
- 2021-08-27 BR BR112023003476A patent/BR112023003476A2/pt unknown
- 2021-08-27 WO PCT/EP2021/073735 patent/WO2022043493A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| IL300668A (en) | 2023-04-01 |
| US20230340055A1 (en) | 2023-10-26 |
| CA3189715A1 (en) | 2022-03-03 |
| WO2022043493A1 (en) | 2022-03-03 |
| KR20230057447A (ko) | 2023-04-28 |
| BR112023003476A2 (pt) | 2023-04-11 |
| JP2023540701A (ja) | 2023-09-26 |
| EP4204439A1 (en) | 2023-07-05 |
| TW202219060A (zh) | 2022-05-16 |
| AU2021335032A1 (en) | 2023-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023002047A (es) | Proteinas de interleucina 2 (il-2) glucosiladas y usos de las mismas. | |
| AR036196A1 (es) | Agentes de contraste multimericos dirigidos a base de peptidos | |
| DE69534569D1 (de) | Hiv-1- und hiv-2-peptide zur hemmung von mit membranfusionen in zusammenhang stehenden phänomenen, einschliesslich der übertragung von hiv | |
| KR960702753A (ko) | Hiv 전이 저해하는 합성 펩티드 | |
| CY1113218T1 (el) | Υβριδιο και διμερης εκφραση πρωτεϊνων ναϊσσεριας | |
| ES2073571T3 (es) | Aplicacion de nuevos fragmentos de adn como secuencia que codifica un peptido señal para la secrecion de proteinas maduras, mediante levaduras recombinantes, cassettes de expresion, levaduras transformadas y procedimiento correspondiente de preparacion de proteinas. | |
| AU9084601A (en) | G-csf analog compositions and methods | |
| BRPI0412799A (pt) | imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura | |
| ES550528A0 (es) | Un procedimiento para producir la proteina apoacuorina | |
| ATE146219T1 (de) | Polypeptid | |
| DK0479948T3 (da) | Sammensætninger og fremgangsmåder til syntese af natriuretisk protein-receptor B og anvendelsesfremgangsmåder | |
| MX2022014082A (es) | Secuencias de interleucina (il-2) y usos de las mismas. | |
| PT851926E (pt) | Variantes do interferao-gama (rhu-ifn-gama) recombinante humano com estabilidade termica melhorada | |
| ATE495247T1 (de) | Chromoprotein und fluoroproteine | |
| BR112022026248A2 (pt) | Conjugados de citocinas | |
| DK39591A (da) | Peptidforbindelser | |
| ATE439856T1 (de) | Verwendung von peptiden, die aus der b beta kette des humanen fibrinogens abgeleitet wurden, zur behandlung von schock | |
| ATE357526T1 (de) | Modifizierte hcv peptid-impfstoffe | |
| CO5060478A1 (es) | Secuencia del gen relacionado con agiopoyetina scarface 3 | |
| IT1277391B1 (it) | Peptidi ciclici analoghi della somatostatina ad attivita' inibitrice dell'ormone della crescita | |
| AR040521A1 (es) | Gen sisntetico que codifica al factor estimulante de colonias de granulocitos humano para la expresion e. coli | |
| NO874704L (no) | Minaktivin fremstilt ved rekombinant dna-teknikk. | |
| DE60234847D1 (de) | N-desoxyribosyltransferase aus lactobacillus, entsprechende nukleinsäuren darauf und ihre verwendungen | |
| IT1262545B (it) | Sistema di espressione per linee cellulari eucariotiche | |
| Elgjo et al. | Growth-inhibiting N-substituted endogenous peptides |